AI assistant
Sending…
Celldex Therapeutics, Inc. — Director's Dealing 2025
Aug 15, 2025
31801_dirs_2025-08-15_1a959504-6430-4c89-a8e5-6113a1009193.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2025-08-13
Reporting Person: Jimenez Freddy A. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-08-13 | Common Stock | S | 341 | $23.9515 | Disposed | 35392 | Direct |
| 2025-08-13 | Common Stock | S | 430 | $25.415 | Disposed | 34962 | Direct |
Footnotes
F1: Includes 269 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
More from Celldex Therapeutics, Inc.
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 1
Major Shareholding Notification
2026
Mar 26